Advanz (Us) Patent-Cliff Exposure & CMS Drug Spending Portfolio

Advanz (Us) (US): 7 reconciled FDA prescription therapies, $30.0M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies7
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$30.0M
2024 Medicare Part D Spend$30.0M
2024 Medicaid Spend$0
California HCAI SB 17 Filings7 WAC filings (max 21.4% 2-yr change)